Search Within

Paul Hamlin

Formats
  1. Meeting Abstract (183)
  2. Journal Article (101)
  3. Research Letter (7)
  4. Correspondence (1)
  5. Review (1)
Groups
  1. Center for Hematologic Malignancies (293)
  2. Department of Medicine (293)
  3. Hematologic Malignancies, Division of (293)
  4. Lymphoma (293)
  5. Population Sciences Research Program (152)
  6. Survivorship Research (145)

More Groups

People
  1. Andrew Zelenetz (186)
  2. Ariela Noy (144)
  3. Steven Horwitz (139)
  4. Maria Palomba (125)
  5. David Straus (122)
  6. Alison Moskowitz (119)

More People

Years
  1. 2025 (6)
  2. 2024 (24)
  3. 2023 (21)
  4. 2022 (12)
  5. 2021 (17)
  6. 2020 (13)

More Years

Publications
  1. Blood (125)
  2. Journal of Clinical Oncology (38)
  3. Hematological Oncology (15)
  4. Annals of Oncology (12)
  5. British Journal of Haematology (12)
  6. Haematologica (10)

More Publications

Publishers
  1. American Society of Hematology (134)
  2. American Society of Clinical Oncology (40)
  3. Wiley Blackwell (19)
  4. Elsevier Inc. (16)
  5. Oxford University Press (13)
  6. John Wiley & Sons (12)

More Publishers

Results (293)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-Cell lymphomas: Results of the MSKCC phase I/II experience
    Meeting Abstract

    O'Connor, O. A.; Hamlin, P. A.; Gerecitano, J.; Portlock, C. S.; Noy, A.; Moskowitz, C.; Straus, D. J.; Sarasohn, D.; Dumitrescu, O.; Pappanicholaou, J.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Early phase experience with pralatrexate (10-propargyl-10-deazaaminopterin [PRX]), a novel antifolate with high affinity for the reduced folate carrier, in patients with chemotherapy refractory lymphoproliferative malignancies
    Meeting Abstract

    O'connor, O.; Hamlin, P.; Neylon, E.; Moskowitz, C.; Portlock, C.; Noy, A.; Sirotnak, F.; Zelenetz, A.; Mould, D.; Horwitz, S.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy confirmed abnormal interim restaging PET scan, improves outcome in patients with advanced stage DLBCL
    Meeting Abstract

    Moskowitz, C.; Hamlin, P. A.; Horwitz, S. M.; Noy, A.; O'Connor, O. A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Lessac-Chenen, S.; Weaver, A.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • FDG-PET scans as a staging study for T-cell lymphomas: High rates of positivity do not result in frequent changes in stage
    Meeting Abstract

    Horwitz, S. M.; Foss, F.; Goldfarb, S.; Molina, A.; Hamlin, P. A.; O'Connor, O. A.; Cammarata, M.; Moskowitz, C. H.; Zelenetz, A. D.
    Blood (2006)

    Fulltext@MSK | Save
  • Relapsed and refractory primary mediastinal diffuse large B-cell lymphoma: Outcome with ICE-based treatment
    Meeting Abstract

    Hamlin, P. A.; Dickson, M.; Kewalramani, T.; Horwitz, S. M.; Portlock, C. S.; Yahalom, J.; Zelenetz, A. D.; Moskowitz, C. H.
    Blood (2006)

    Fulltext@MSK | Save
  • The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, in patients with relapsed/refractory indolent B-cell lymphomproliferative disorders
    Meeting Abstract

    Gerecitano, J.; Portlock, C.; Noy, A.; Hamlin, P.; Moskowitz, C.; Straus, D.; Horwitz, S. M.; Palomba, M. L.; Dumitrescu, O. L.; Pappanicholaou, J.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Feasibility of a self-administered geriatric assessment for cancer patients
    Meeting Abstract

    Gardes, J. H.; Zuckerman, E.; Lichtman, S. M.; Hamlin, P.; Kelly, E.; Lachs, M.; Hurria, A.
    Journal of the American Geriatrics Society (2006)

    Fulltext@MSK | Save
  • Phase III trial of active immunotherapy (FavId (R), Id/KLH) following rituximab induction therapy: Clinical responses in patients (pts) with follicular non-Hodgkin's lymphoma (fNHL)
    Meeting Abstract

    Freedman, A. S.; Hamlin, P. A.; Neelapu, S.; Nichols, C.; Robertson, M.; Bergier, G.; Winter, J. N.; Polikoff, J.; Lin, T.; Pohlman, B.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • New drugs for the treatment of advanced-stage diffuse large cell lymphomas
    Journal Article

    O'Connor, O. A.; Hamlin, P.
    Seminars in Hematology (2006)

    Fulltext@MSK | Save
  • Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: A retrospective analysis of a uniformly-treated patient population
    Journal Article

    Liedtke, M.; Hamlin, P. A.; Moskowitz, C. H.; Zelenetz, A. D.
    Annals of Oncology (2006)

    Fulltext@MSK | Save